NASDAQ:ALLO Allogene Therapeutics - ALLO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.03 +0.01 (+0.20%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.96▼$5.2050-Day Range$5.02▼$8.2152-Week Range$4.91▼$17.49Volume1.29 million shsAverage Volume1.91 million shsMarket Capitalization$726.84 millionP/E RatioN/ADividend YieldN/APrice Target$17.69 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Allogene Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.62 Rating ScoreUpside/Downside251.7% Upside$17.69 Price TargetShort InterestBearish49.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 9 Articles This WeekInsider TradingSelling Shares$41,670 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.45) to ($2.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector424th out of 995 stocksBiological Products, Except Diagnostic Industry75th out of 166 stocks 4.3 Analyst's Opinion Consensus RatingAllogene Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.62, and is based on 9 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.69, Allogene Therapeutics has a forecasted upside of 251.7% from its current price of $5.03.Amount of Analyst CoverageAllogene Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted49.63% of the float of Allogene Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllogene Therapeutics has a short interest ratio ("days to cover") of 20.9, which indicates bearish sentiment.Change versus previous monthShort interest in Allogene Therapeutics has recently increased by 7.98%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAllogene Therapeutics does not currently pay a dividend.Dividend GrowthAllogene Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALLO. Previous Next 2.4 News and Social Media Coverage News SentimentAllogene Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Allogene Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 23 people have searched for ALLO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allogene Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,670.00 in company stock.Percentage Held by Insiders29.80% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.94% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Allogene Therapeutics are expected to decrease in the coming year, from ($2.45) to ($2.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allogene Therapeutics is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allogene Therapeutics is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllogene Therapeutics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Allogene Therapeutics (NASDAQ:ALLO) StockAllogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.Read More Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLO Stock News HeadlinesMarch 24, 2023 | americanbankingnews.comAllogene Therapeutics (NASDAQ:ALLO) Hits New 52-Week Low at $5.20March 21, 2023 | markets.businessinsider.com10 Analysts Have This to Say About Allogene TherapeuticsMarch 27, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 21, 2023 | americanbankingnews.comAllogene Therapeutics (NASDAQ:ALLO) Coverage Initiated by Analysts at Sanford C. BernsteinMarch 18, 2023 | americanbankingnews.comAllogene Therapeutics (NASDAQ:ALLO) Reaches New 52-Week Low at $5.36March 18, 2023 | americanbankingnews.comAnalysts Offer Predictions for Allogene Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ALLO)March 17, 2023 | americanbankingnews.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) to Post Q1 2023 Earnings of ($0.60) Per Share, Zacks Research ForecastsMarch 11, 2023 | bizjournals.comBiotechs scramble to assure investors of minimal SVB exposureMarch 27, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 6, 2023 | finance.yahoo.comAfter Plunging -23.01% in 4 Weeks, Here's Why the Trend Might Reverse for Allogene Therapeutics (ALLO)March 5, 2023 | seekingalpha.comAllogene: ALLO-715 Phase 1 Results And ALLO-213 Preclinical Data Is PromisingMarch 3, 2023 | msn.comAllogene Therapeutics's Return On Capital Employed InsightsMarch 2, 2023 | markets.businessinsider.comWhat 10 Analyst Ratings Have To Say About Allogene TherapeuticsMarch 2, 2023 | finance.yahoo.comJazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive SalesMarch 2, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Allogene Therapeutics (ALLO)March 1, 2023 | finance.yahoo.comAllogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 1, 2023 | finance.yahoo.comAllogene Therapeutics (ALLO) Reports Q4 Loss, Misses Revenue EstimatesMarch 1, 2023 | finance.yahoo.comAllogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular TherapyMarch 1, 2023 | finance.yahoo.comQ4 2022 Allogene Therapeutics Inc Earnings CallFebruary 28, 2023 | msn.comDenali (DNLI) Q4 Earnings Beat Estimates, Pipeline in FocusFebruary 28, 2023 | finance.yahoo.comPerrigo (PRGO) Beats Q4 Earnings Estimates, Lags on SalesFebruary 21, 2023 | finance.yahoo.comAllogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023February 16, 2023 | finance.yahoo.comGuardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseFebruary 15, 2023 | marketwatch.comCAR T-Cell Therapy Market Size 2023 With Economical Benchmarking, Old Statistics & Forecasts, Company Returns SharesFebruary 15, 2023 | finance.yahoo.comAllogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseFebruary 10, 2023 | finance.yahoo.comJPMorgan’s Best Performing 15 Stock Picks for 2023February 3, 2023 | finance.yahoo.com4 Biotech Stocks Set to Outpace Q4 Earnings EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLO Company Calendar Last Earnings2/28/2023Today3/27/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLO CUSIPN/A CIK1737287 Webwww.allogene.com Phone(650) 457-2700FaxN/AEmployees308Year Founded2018Price Target and Rating Average Stock Price Forecast$17.69 High Stock Price Forecast$31.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+251.7%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-332,630,000.00 Net Margins-136,885.59% Pretax Margin-136,885.59% Return on Equity-43.44% Return on Assets-36.79% Debt Debt-to-Equity RatioN/A Current Ratio9.70 Quick Ratio9.70 Sales & Book Value Annual Sales$240,000.00 Price / Sales3,028.48 Cash FlowN/A Price / Cash FlowN/A Book Value$4.62 per share Price / Book1.09Miscellaneous Outstanding Shares144,500,000Free Float101,437,000Market Cap$726.84 million OptionableNot Optionable Beta0.81 Social Links Key ExecutivesDavid D. ChangPresident, Chief Executive Officer & DirectorEric SchmidtChief Financial OfficerBarbra SasuChief Scientific OfficerAlison MooreChief Technical OfficerArun BalakumaranChief Medical OfficerKey CompetitorsImmunityBioNASDAQ:IBRXExscientiaNASDAQ:EXAIValnevaNASDAQ:VALNAnavex Life SciencesNASDAQ:AVXLSana BiotechnologyNASDAQ:SANAView All CompetitorsInsiders & InstitutionsPoint72 Middle East FZEBought 56,220 shares on 2/16/2023Ownership: 0.039%State of Wisconsin Investment BoardSold 5,281 shares on 2/15/2023Ownership: 0.057%E Fund Management Co. Ltd.Bought 8,037 shares on 2/15/2023Ownership: 0.027%Delphia USA Inc.Bought 8,202 shares on 2/15/2023Ownership: 0.022%Capital Impact Advisors LLCSold 2,638 shares on 2/15/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions ALLO Stock - Frequently Asked Questions Should I buy or sell Allogene Therapeutics stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALLO shares. View ALLO analyst ratings or view top-rated stocks. What is Allogene Therapeutics' stock price forecast for 2023? 13 brokers have issued 1 year price targets for Allogene Therapeutics' stock. Their ALLO share price forecasts range from $6.00 to $31.00. On average, they expect the company's stock price to reach $17.69 in the next year. This suggests a possible upside of 251.7% from the stock's current price. View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts. How have ALLO shares performed in 2023? Allogene Therapeutics' stock was trading at $6.29 at the start of the year. Since then, ALLO shares have decreased by 20.0% and is now trading at $5.03. View the best growth stocks for 2023 here. Are investors shorting Allogene Therapeutics? Allogene Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 39,800,000 shares, an increase of 8.0% from the February 28th total of 36,860,000 shares. Based on an average daily trading volume, of 1,900,000 shares, the days-to-cover ratio is currently 20.9 days. Approximately 49.6% of the shares of the company are short sold. View Allogene Therapeutics' Short Interest. When is Allogene Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our ALLO earnings forecast. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics, Inc. (NASDAQ:ALLO) posted its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.05. The company earned $0.05 million during the quarter, compared to analyst estimates of $0.06 million. Allogene Therapeutics had a negative trailing twelve-month return on equity of 43.44% and a negative net margin of 136,885.59%. The firm's quarterly revenue was down 6.0% on a year-over-year basis. During the same period last year, the company earned ($0.54) earnings per share. What ETFs hold Allogene Therapeutics' stock? ETFs with the largest weight of Allogene Therapeutics (NASDAQ:ALLO) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Kelly CRISPR & Gene Editing Technology ETF (XDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), WisdomTree BioRevolution Fund (WDNA) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What is David Chang's approval rating as Allogene Therapeutics' CEO? 2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP). When did Allogene Therapeutics IPO? (ALLO) raised $272 million in an initial public offering on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO. What is Allogene Therapeutics' stock symbol? Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO." Who are Allogene Therapeutics' major shareholders? Allogene Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (4.12%), JPMorgan Chase & Co. (2.61%), Millennium Management LLC (2.27%), Dimensional Fund Advisors LP (1.66%), Geode Capital Management LLC (1.18%) and Two Sigma Investments LP (1.12%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri. View institutional ownership trends. How do I buy shares of Allogene Therapeutics? Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Allogene Therapeutics' stock price today? One share of ALLO stock can currently be purchased for approximately $5.03. How much money does Allogene Therapeutics make? Allogene Therapeutics (NASDAQ:ALLO) has a market capitalization of $726.84 million and generates $240,000.00 in revenue each year. The company earns $-332,630,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. How many employees does Allogene Therapeutics have? The company employs 308 workers across the globe. How can I contact Allogene Therapeutics? Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.allogene.com. The company can be reached via phone at (650) 457-2700 or via email at ir@allogene.com. This page (NASDAQ:ALLO) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.